EUVIMEDEUVIMED entdecken
Crossref

Synergistic effects of BET inhibitors and ferroptosis inducers via targeted inhibition of the BRD4/c-Myc/NRF2 pathway in AML

Mengjun Zhong, Shuxin Zhong, Kangjie Qiu, Xueting Peng, Xin Liu, Songnan Sui, Zhangshuai Dai, Xianfeng Wang, Dingrui Nie, Zhi Yu, Quan Yu, Cunte Chen und 2 weitere

European Journal of Pharmacology · 2025

DOI: 10.1016/j.ejphar.2025.177652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025. Verfasst von Mengjun Zhong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, …. Hauptthemen laut MEDLINE: Ferroptosis, Leukemia, Myeloid, Acute, NF-E2-Related Factor 2, Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Major Research Plan, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In acute myeloid leukemia (AML), high expression of BRD4 is associated with poor prognosis. BET inhibitors that mainly inhibit BRD4 can induce AML cell death, but some AML cells are insensitive to BET inhibitors. We found that BET inhibitors could promote the up-regulation of the ferroptosis signaling pathway in AML. In this study, we intend to investigate the synergistic effects of BET inhibitors with ferroptosis inducers in AML cells. The combination of BET inhibitors with ferroptosis inducers (RSL3, FIN56, and Erastin) markedly reduced AML cell viability and increased cell death, as demonstrated by CCK-8 assays and flow cytometry analysis across multiple AML cell lines and primary AML patient samples. Moreover, BET inhibitors combined with ferroptosis inducers elevated the lipid reactive oxygen species (ROS) levels, indicating heightened lipid peroxidation, a hallmark of ferroptosis. Mechanistically, BET inhibitor and ferroptosis inducer co-targeted the BRD4/c-Myc/NRF2 axis, leading to downregulation of NRF2, key regulators of AML cell survival and oxidative stress resistance. NRF2 knockdown amplified the anti-AML effect of this combined treatment, whereas NRF2 overexpression negated this synergy, highlighting its critical role in mediating ferroptosis resistance. Finally, survival analyses of AML patients from the TCGA and GSE71014 datasets revealed that elevated expression of BRD4, NRF2, and its downstream target GPX4, an essential ferroptosis regulator, correlated with poor overall survival, highlighting the clinical relevance of our findings. In all, combining BET inhibition with ferroptosis induction could enhance anti-leukemia effect and represent a novel therapeutic strategy for targeting AML cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisLeukemia, Myeloid, AcuteNF-E2-Related Factor 2Proto-Oncogene Proteins c-mycTranscription FactorsCell Cycle ProteinsAntineoplastic AgentsHumansDrug SynergismCell Line, TumorSignal TransductionReactive Oxygen SpeciesCell SurvivalBromodomain Containing ProteinsCarbolinesPiperazines

Stichwörter der Autor:innen

AMLBET inhibitorFerroptosis inducerNRF2

Substanzen

NF-E2-Related Factor 2BRD4 protein, humanProto-Oncogene Proteins c-mycTranscription FactorsNFE2L2 protein, humanCell Cycle ProteinsMYC protein, humanReactive Oxygen SpeciesAntineoplastic AgentsRSL3 compound

Autor:innen und Institutionen

  • Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, PR China; Department of Hematology, Guangzhou First People's Hospital,…
  • Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, PR China.
  • Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, PR China; Department of Hematology, First Affiliated Hospital, Jinan U…
  • Department of Hematology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510700, PR China.
  • Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, PR China.
  • Experimental Research Center, School of Medicine, Jinan University, Guangzhou, 510632, PR China. Electronic address: 635452450@qq.com.

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Major Research Plan
  • National Natural Science Foundation of China
  • Guangzhou Municipal Science and Technology Project

Zitieren

APA

Zhong, M., Zhong, S., Qiu, K., Peng, X., Liu, X., Sui, S., Dai, Z., Wang, X., Nie, D., Yu, Z., Yu, Q., Chen, C., Li, Y., & Zeng, C. (2025). Synergistic effects of BET inhibitors and ferroptosis inducers via targeted inhibition of the BRD4/c-Myc/NRF2 pathway in AML. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.177652

Vancouver

Zhong M, Zhong S, Qiu K, Peng X, Liu X, Sui S, et al. Synergistic effects of BET inhibitors and ferroptosis inducers via targeted inhibition of the BRD4/c-Myc/NRF2 pathway in AML. European Journal of Pharmacology. 2025. doi:10.1016/j.ejphar.2025.177652

BibTeX
@article{Zhong2025,
  author = {Zhong, Mengjun and Zhong, Shuxin and Qiu, Kangjie and Peng, Xueting and Liu, Xin and Sui, Songnan and Dai, Zhangshuai and Wang, Xianfeng and Nie, Dingrui and Yu, Zhi and Yu, Quan and Chen, Cunte and Li, Yangqiu and Zeng, Chengwu},
  title = {Synergistic effects of BET inhibitors and ferroptosis inducers via targeted inhibition of the BRD4/c-Myc/NRF2 pathway in AML},
  journal = {European Journal of Pharmacology},
  year = {2025},
  doi = {10.1016/j.ejphar.2025.177652}
}
Kostenlos starten →